Table 2.
Effect of digoxin on outcomes at the study end in systolic & diastolic heart failure (HF) patients
| Outcomes | Original data (N=7788) with 6800 SHF and 988 DHF patients | ||||
|---|---|---|---|---|---|
| Systolic HF* | Placebo (n=3403) | Digoxin (n=3397) | Absolute rate difference (%) | Hazard ratio (95% CI) | P value |
|
|
|||||
| HF hospitalization or HF mortality | 1291 (38%) | 1041 (31%) | − 7.3 | 0.75 (0.69–0.82) | <0.001 |
| HF hospitalization | 1180 (35%) | 910 (27%) | − 7.9 | 0.72 (0.66–0.79) | <0.001 |
|
|
|||||
| Diastolic HF† | Placebo (n=496) | Digoxin (n=492) | Absolute rate difference (%) | Hazard ratio (95% CI) | P value |
|
|
|||||
| HF hospitalization or HF mortality | 119 (24%) | 102 (21%) | − 3.3 | 0.82 (0.63–1.07) | 0.136 |
| HF hospitalization | 108 (22%) | 89 (18%) | − 3.7 | 0.79 (0.59–1.04) | 0.094 |
| Matched data (N=1832) with 916 SHF and 916 DHF patients
|
|||||
| Systolic HF | Placebo (n=450) | Digoxin (n=466) | Absolute rate difference (%) | Hazard ratio (95% CI) | P value |
|
|
|||||
| HF hospitalization or HF mortality | 143 (32%) | 132 (28%) | − 3.5 | 0.85 (0.67–1.08) | 0.188 |
| HF hospitalization | 131 (29%) | 113 (24%) | − 4.9 | 0.80 (0.62–1.03) | 0.079 |
|
|
|||||
| Diastolic HF | Placebo (n=460) | Digoxin (n=456) | Absolute rate difference (%) | Hazard ratio (95% CI) | P value |
|
|
|||||
| HF hospitalization or HF mortality | 113 (25%) | 93 (20%) | − 4.2 | 0.79 (0.60–1.03) | 0.085 |
| HF hospitalization | 102 (22%) | 82 (18%) | − 4.2 | 0.77 (0.57–1.03) | 0.074 |
*
Adapted from: The Digitalis Investigation Group Investigators. N Engl J Med 1997;336:525–533.
†
Adapted from: Ahmed A, et al. Circulation 2006; 114(5):397–403.